Connect Biopharma Holdings LtdCNTBEarnings & Financial Report
Nasdaq
Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Panacea Innovation Limited | 24.30% | 13.4M | ▲ +2.50pp | 2024-07-01 |
| Zheng Wei | 11.70% | 6.5M | — | 2024-02-13 |
| BioFortune Inc. | 11.20% | 6.2M | — | 2024-02-13 |
| RA Capital Management, L.P. | 0.00% | 207.5M | ▼ -5.60pp | 2024-02-27 |
| Panacea Opportunity Fund I, L.P. | 0.00% | 207.5M | — | 2023-10-04 |
Insider Transactions
Net 90d: +$4.00M · buys $4.00M / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-31 | Xanthopoulos Kleanthis Gabriel | Director | Grant | 2.8K | $0.00 | $0 |
| 2026-03-31 | LIU JEAN I | Director | Grant | 5.1K | $0.00 | $0 |
| 2026-03-31 | James Huang | Director | Buy (open market) | 1.16M | $3.45 | $4.00M |
1–3 of 3